Immunotherapy for Lymphoma Source: Society for Immunotherapy of Cancer February 20, 2026

https://reference.medscape.com/cc2/p10/sitc-guideline-immunotherapy-lymphoma-2026a10004e3?ecd=WNL_drugguide_260311_MSCPREF_onc_etid8172632&uac=148436CN&impID=8172632 This Medscape summary highlights February 2025 revisions to the SITC clinical practice guideline for immunotherapy in lymphoma, which was originally established in 2020. The summary provides oncologists and hematologists with streamlined recommendations regarding the optimal scheduling and integration of FDA-approved immunotherapies, as well as the specialized management of irAEs. The guidance is derived from a combination of published literature and expert clinical experience. It incorporates 2025 updates, including revised FDA black box warnings and corrected clinical data. This summary is intended for quick clinical reference; for deep-dive rationale, background, and full evidence tables, please refer to the complete SITC publication.